1-4 of 4
Ulrike Kuckelkorn
Close
Sort by
Journal Articles

Antitumor Activity of a Novel Proteasome Inhibitor BSc2118 Against Multiple Myeloma

Meirong Zang, PhD, Lanting Liu, Xin Li, Wei Li, MD, Ulrike Kuckelkorn, Wen Zhou, PhD, Lugui Qiu, MD, Fengyan Jin, MD
Journal: Blood
Blood (2014) 124 (21): 5725.
https://doi.org/10.1182/blood.V124.21.5725.5725
Published: 2014
Journal Articles

The Proteasome Inhibitor BSc2118 Causes Growth Inhibition, Cell Cycle Arrest and Cyclin D1 Degradation in Mantle Cell Lymphoma Cell Lines.

Christian Jakob, MD, Jan Sterz, MD, Ivana von Metzler, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Susanne Rötzer, MD, Martin Kaiser, MD, Ulrike Heider, MD, Jessica Rademacher, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD
Journal: Blood
Blood (2007) 110 (11): 1401.
https://doi.org/10.1182/blood.V110.11.1401.1401
Published: 2007
Journal Articles

BSc2118, a Novel Proteasome Inhibitor, Shows Anti-Tumor Activity in Multiple Myeloma and Mantle Cell Lymphoma.

Jan Sterz, MD, Christian Jakob, MD, Ulrike Kuckelkorn, PhD, Hannes A. Braun, PhD, Martin Kaiser, MD, Claudia Fleissner, MD, Lorenz Kleeberg, MD, Ulrike Heider, MD, Kurt Possinger, MD, Peter M. Kloetzel, PhD, Orhan Sezer, MD, Ivana Zavrski, MD
Journal: Blood
Blood (2006) 108 (11): 3475.
https://doi.org/10.1182/blood.V108.11.3475.3475
Published: 2006
Journal Articles

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma

Clinical Trials & Observations
Christian Jakob, Karl Egerer, Peter Liebisch, Seval Türkmen, Ivana Zavrski, Ulrike Kuckelkorn, Ulrike Heider, Martin Kaiser, Claudia Fleissner, Jan Sterz, Lorenz Kleeberg, Eugen Feist, Gerd-R. Burmester, Peter-M. Kloetzel, Orhan Sezer
Journal: Blood
Blood (2006) 109 (5): 2100–2105.
https://doi.org/10.1182/blood-2006-04-016360
Published: 2006